NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

表紙
市場調查報告書

思覺失調症 - 競爭情形:2020年

Schizophrenia - Competitive Landscape in 2020

出版商 GlobalData 商品編碼 995610
出版日期 內容資訊 英文 61 Pages
訂單完成後即時交付
價格
思覺失調症 - 競爭情形:2020年 Schizophrenia - Competitive Landscape in 2020
出版日期: 2020年11月30日內容資訊: 英文 61 Pages
簡介

藥物開發企業主要的焦點,是5-hydroxytryptamine(5-HT)和多巴胺受體。在開發平台有143種藥物,其中39種以5-HT或多巴胺受體作為標的。在這個適應症,大型製藥企業支配著研究開發。預計發生率增加,促進思覺失調症治療藥市場成長。

本報告提供全球思覺失調症治療藥的現在、未來的競爭情形相關的系統性資訊。

目錄

第1章 目錄

第2章 摘要整理

第3章 簡介

第4章 上市藥的評估

  • 上市藥概要
  • 上市藥的簡介

第5章 開發平台的評估

  • 開發平台概要
  • 開發平台的明細:各地區
  • 開發平台的明細:各分子類型,各標的
  • 醫藥品審查的指定
  • 相變的成功率
  • 核準的可能性

第6章 臨床試驗的評估

  • 臨床試驗概要:各階段
  • 概要:各地區
  • 治療領域預測
  • 主要贊助商
  • 登記分析
  • 實行可能性分析

第7章 商業性評估

  • 未來市場促進因素

第8章 社群媒體與數位行銷

  • 主要的Twitter Chatter
  • 領導品牌的網站
  • 信任來源和引用來源

第9章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDHC030CL

GlobalData's "Schizophrenia - Competitive Landscape in 2020" combines data from the Pharma Intelligence Center with in-house analyst expertise to provide a competitive assessment of the disease marketplace.

5-hydroxytryptamine (5-HT) and dopamine receptors are the major focus of drug developers. There are 143 drugs in the pipeline, 39 of which targets 5-HT or dopamine receptors. Big pharma dominates R&D in this indication, with Otsuka, Johnson & Johnson, Lundbeck, and Roche leading the way. Increasing incidence expected to drive growth in schizophrenia market. The increasing awareness and approval of late-stage pipeline molecules will drive the market's growth over the coming years, but lack of curative treatment and increasing generic penetration will limit the growth.

This reports provides a data-driven overview of the current and future competitive landscape in schizophrenia therapeutics.

Scope

Components of the report include -

  • Disease epidemiology
  • Marketed drugs assessment
  • Pipeline drugs assessment
  • Clinical trials assessment
  • Commercial assessment
  • Social media overview
  • Digital marketing overview

Reasons to Buy

  • Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
  • Develop business strategies by understanding the trends shaping and driving the global schizophrenia market.
  • Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the global schizophrenia market in the future.
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
  • Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
  • Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.

Table of Contents

1.Table of Contents

  • 1.1 Preface
  • 1.2 Abbreviations
  • 1.3 Related Reports
  • 1.4 Upcoming Related Reports

2 Executive Summary

  • 2.1 Key Findings
  • 2.2 Key Events

3 Introduction

  • 3.1 Report Scope
  • 3.2 Disease Overview Epidemiology Overview
  • 3.3 Epidemiology

4 Marketed Drugs Assessment

  • 4.1 Marketed Drugs Overview
  • 4.2 Marketed Drug Profiles

5 Pipeline Assessment

  • 5.1 Pipeline Overview
  • 5.2 Pipeline Breakdown by Region
  • 5.3 Pipeline Breakdown by Molecule Type and Target
  • 5.4 Drug Review Designations
  • 5.5 Phase Transition Success Rates
  • 5.6 Likelihood of Approval

6 Clinical Trial Assessment

  • 6.1 Clinical Trials Overview by Phase
  • 6.2 Overview by Region
  • 6.4 Therapy Area Perspective
  • 6.4 Leading Sponsors
  • 6.5 Enrollment Analytics
  • 6.6 Feasibility Analysis

7 Commercial Assessment

  • 7.1 Upcoming Market Catalysts

8 Social Media and Digital Marketing

  • 8.1 Key Twitter Chatter
  • 8.2 Top Branded Websites
  • 8.3 Trust Flow and Citation Flow

9 Appendix

  • 9.1 Methodology
  • 9.2 About the Authors
  • 9.3 About GlobalData
  • 9.4 Contact Us
  • 9.5 Disclaimer